Clinical Program Equipment & Supplies

Biotron is developing novel small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and ...

A humanized monoclonal antibody, is an antagonist of the alpha chain of the interleukine-7 receptor, CD127, present on T effector cells, thus down regulating the immune activity. Interleukin-7 (IL-7) is a cytokine that controls the proliferation, apoptosis and activation of CD4 and CD8 effector T-cells in ...

a monoclonal antibody fragment and CD28 antagonist, selectively blunts CD28 co-stimulation while sparing the CTLA-4 co-inhibitory signal. The net effect of CD28 antagonism is down regulating effector T-cells while promoting T-Reg activity. The CD28/CTLA-4 pathway controls both T-cell activation and regulatory T-cell down regulation. CD28 receptor is expressed on the surface of the majority of ...

CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, SARS and MERS, to ...

In recent years, immunotherapies have driven significant clinical progress and increased hopes for patients suffering from various types of cancer. The tumor microenvironment (TME), in particular the presence and immune-status of myeloid derived suppressor cells (MDSC), tumor-associated macrophages (TAM) as well as dendritic cells, has been closely linked to tumor activity and ...

Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...

Discussions are underway for the design of a clinical program in this indication together with a manufacturer of catheter devices suitable for direct myocardial injection of APO-1 ...

We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled ...

Oral, once-daily, direct factor Xa (pronounced “Ten A”) inhibitor. More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, which is comprised of more than 10 RCTs (randomized, controlled trials), non-interventional studies and registries, including completed, ongoing and future research. ...

Sirolimus is the most widely known mTOR inhibitor with a well-established safety and effectiveness profile in various treatment applications: Drug-eluting stents, Transplant, Oncology. Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX™, DESyne®, ...

While Alzheimer’s is the largest tauopathy, other tauopathies are rare diseases that present accelerated regulatory pathways and significant near-term commercial opportunities. These rare diseases shown in Chart A below have a tau etiology similar to AD. Oligomerix’s 1st clinical program focuses on demonstrating safety and efficacy of our lead ...

CT-132 is under development as a clinically-validated digital program for ...

The CO Check+ is an innovative smoking cessation tool designed specifically for use in smoking cessation programs and clinics. One single breath of expiration into the CO Check+ provides instant results in PPM and %COHb via the large, easy-to-read ...

CT-161 is under development as a clinically-validated digital program for overactive ...

Microbion has two Phase 2 clinical programs in diabetic foot ulcer infection and orthopedic implant infection. In addition, preclinical programs are under development for multiple therapeutic indications, including the treatment of serious respiratory ...

Clickadian is under development as a clinically-validated fully digital program for ...

Posoleucel targets five devastating viral pathogens: BK virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein-Barr Virus (EBV), and Human Herpesvirus 6 (HHV-6), and has the potential to transform care for transplant recipients. ...

Yso1 is a clinical stage development program aiming at harnessing the potential of Christensenella minuta as a groundbreaking biotherapy to treating obesity and metabolic disorders. The goal of our disruptive approach is to return to obese patients christensenella, which have the unique ability to repair the unbalanced microbiome, thereby restoring impaired key ...

With a fast and easy-to-administer collection process, Intercept is ideal for workplace, criminal justice, drug treatment centers, and clinical setting screening programs, among ...

GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science. Through what we believe to be one of the largest clinical study programs ever pursued in genomic medicine, GRAIL is creating vast datasets to develop evidence supporting our ...